These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32733447)

  • 1. Development of Spherical Nucleic Acids for Prostate Cancer Immunotherapy.
    Qin L; Wang S; Dominguez D; Long A; Chen S; Fan J; Ahn J; Skakuj K; Huang Z; Lee A; Mirkin C; Zhang B
    Front Immunol; 2020; 11():1333. PubMed ID: 32733447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer.
    Callmann CE; Cole LE; Kusmierz CD; Huang Z; Horiuchi D; Mirkin CA
    Proc Natl Acad Sci U S A; 2020 Jul; 117(30):17543-17550. PubMed ID: 32669433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunostimulatory CpG-DNA and PSA-peptide vaccination elicits profound cytotoxic T cell responses.
    Maurer T; Pournaras C; Aguilar-Pimentel JA; Thalgott M; Horn T; Heck M; Heit A; Kuebler H; Gschwend JE; Nawroth R
    Urol Oncol; 2013 Oct; 31(7):1395-401. PubMed ID: 21982682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
    Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
    Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The STEAP1(262-270) peptide encapsulated into PLGA microspheres elicits strong cytotoxic T cell immunity in HLA-A*0201 transgenic mice--A new approach to immunotherapy against prostate carcinoma.
    Herrmann VL; Wieland DE; Legler DF; Wittmann V; Groettrup M
    Prostate; 2016 Apr; 76(5):456-68. PubMed ID: 26715028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
    Lubaroff DM; Karan D
    Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide.
    Miconnet I; Koenig S; Speiser D; Krieg A; Guillaume P; Cerottini JC; Romero P
    J Immunol; 2002 Feb; 168(3):1212-8. PubMed ID: 11801657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
    Davila E; Celis E
    J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity.
    Shirota H; Klinman DM
    Cancer Immunol Immunother; 2011 May; 60(5):659-69. PubMed ID: 21318638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis.
    Xu Z; Ramishetti S; Tseng YC; Guo S; Wang Y; Huang L
    J Control Release; 2013 Nov; 172(1):259-265. PubMed ID: 24004885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant.
    Jérôme V; Graser A; Müller R; Kontermann RE; Konur A
    J Immunother; 2006; 29(3):294-305. PubMed ID: 16699372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice.
    Nierkens S; den Brok MH; Roelofsen T; Wagenaars JA; Figdor CG; Ruers TJ; Adema GJ
    PLoS One; 2009 Dec; 4(12):e8368. PubMed ID: 20020049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with antigenic peptides complexed with β-glucan induces potent cytotoxic T-lymphocyte activity in combination with CpG-ODNs.
    Mochizuki S; Morishita H; Kobiyama K; Aoshi T; Ishii KJ; Sakurai K
    J Control Release; 2015 Dec; 220(Pt A):495-502. PubMed ID: 26562685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
    Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
    J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine.
    Parenky AC; Akalkotkar A; Mulla NS; D'Souza MJ
    Vaccine; 2019 Sep; 37(41):6085-6092. PubMed ID: 31477437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heat shock protein-antigen fusions lose their enhanced immunostimulatory capacity after endotoxin depletion.
    Marincek BC; Kühnle MC; Srokowski C; Schild H; Hämmerling G; Momburg F
    Mol Immunol; 2008 Nov; 46(1):181-91. PubMed ID: 18804283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Photochemical Internalization of Peptide Antigens Provides a Novel Strategy to Realize Therapeutic Cancer Vaccination.
    Haug M; Brede G; Håkerud M; Nedberg AG; Gederaas OA; Flo TH; Edwards VT; Selbo PK; Høgset A; Halaas Ø
    Front Immunol; 2018; 9():650. PubMed ID: 29670624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.